-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 4, 2021, Atara Biotherapeutics announced that T cell immunotherapy tabelecleucel (tab-cel) is a critical phase 3 in the treatment of EB virus (EBV)-related post-transplant lymphoproliferative disease (EBV+PTLD) Positive results in clinical trials
EBV+PTLD is a type of lymphoma, a serious blood cancer, which may occur after solid organ transplantation (SOT) or allogeneic hematopoietic cell transplantation (HCT)
Tab-cel is a ready-to-use allogeneic T cell immunotherapy
In this ongoing Phase 3 trial, as of May 2021, 38 evaluable patients (24 after SOT and 14 after HCT) have observed an average ORR of 50% (19/38, 95% CI: 33.
▲Tab-cel Phase 3 clinical trial results (picture source: Atara Biotherapeutics official website)
Among the 19 patients who achieved remission, 11 had a duration of remission (DOR) of more than 6 months, and the median DOR had not yet been reached
The safety aspect is consistent with previously published data, and no new signals or problems have been reported
Reference materials:
[1] Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data.
(The original text has been deleted)
